Literature DB >> 24025942

Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.

Tonya N Taylor1, Shawn P Alter, Minzheng Wang, David S Goldstein, Gary W Miller.   

Abstract

Parkinson's disease (PD) is the most common neurodegenerative motor disease. Pathologically, PD is characterized by Lewy body deposition and subsequent death of dopamine neurons in the substantia nigra pars compacta. PD also consistently features degeneration of the locus ceruleus, the main source of norepinephrine in the central nervous system. We have previously reported a mouse model of dopaminergic neurodegeneration based on reduced expression of the vesicular monoamine transporter (VMAT2 LO). To determine if reduced vesicular storage can also cause noradrenergic degeneration, we examined indices of damage to the catecholaminergic systems in brain and cardiac tissue of VMAT2 LO mice. At two months of age, neurochemical analyses revealed substantial reductions in striatal dopamine (94%), cortical dopamine (57%) and norepinephrine (54%), as well as cardiac norepinephrine (97%). These losses were accompanied by increased conversion of dopamine and norepinephrine to their deaminated metabolites. VMAT2 LO mice exhibited loss of noradrenergic innervation in the cortex, as determined by norepinephrine transporter immunoreactivity and (3)H-nisoxetine binding. Using unbiased stereological techniques, we observed progressive degeneration in the locus ceruleus that preceded degeneration of the substantia nigra pars compacta. In contrast, the ventral tegmental area, which is spared in human PD, remained unaffected. The coordinate loss of dopamine and norepinephrine neurons in VMAT2 LO mice parallels the pattern of neurodegeneration that occurs in human PD, and demonstrates that insufficient catecholamine storage can cause spontaneous degeneration in susceptible neurons, underscoring cytosolic catecholamine catabolism as a determinant of neuronal susceptibility in PD. This article is part of the Special Issue entitled 'The Synaptic Basis of Neurodegenerative Disorders'.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3,4-dihydroxyphenylacetaldehyde; 3,4-dihydroxyphenylacetic acid; 3,4-dihydroxyphenylglycol; 3-4-dihydroxyphenylglycolaldehyde; DA; DHPG; DOPAC; DOPAL; DOPEGAL; LC; Locus ceruleus; MAO; NE; NET; Norepinephrine; Parkinson's disease; SNpc; TH; VMAT2; VTA; dopamine; locus ceruleus; monoamine oxidase; norepinephrine; norepinephrine transporter; substantia nigra pars compacta; tyrosine hydroxylase; ventral tegmental area; vesicular monoamine transporter 2

Mesh:

Substances:

Year:  2013        PMID: 24025942      PMCID: PMC4049095          DOI: 10.1016/j.neuropharm.2013.08.033

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  57 in total

Review 1.  Altered vesicular dopamine storage in Parkinson's disease: a premature demise.

Authors:  W Michael Caudle; Rebecca E Colebrooke; Piers C Emson; Gary W Miller
Journal:  Trends Neurosci       Date:  2008-05-09       Impact factor: 13.837

2.  Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease.

Authors:  G M Halliday; P C Blumbergs; R G Cotton; W W Blessing; L B Geffen
Journal:  Brain Res       Date:  1990-02-26       Impact factor: 3.252

3.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

4.  Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine.

Authors:  Y M Wang; R R Gainetdinov; F Fumagalli; F Xu; S R Jones; C B Bock; G W Miller; R M Wightman; M G Caron
Journal:  Neuron       Date:  1997-12       Impact factor: 17.173

Review 5.  Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia.

Authors:  Kelly Del Tredici; Heiko Braak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-10-13       Impact factor: 10.154

6.  Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection.

Authors:  C Holmes; G Eisenhofer; D S Goldstein
Journal:  J Chromatogr B Biomed Appl       Date:  1994-03-04

Review 7.  Dysautonomia in Parkinson's disease: neurocardiological abnormalities.

Authors:  David S Goldstein
Journal:  Lancet Neurol       Date:  2003-11       Impact factor: 44.182

8.  Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress.

Authors:  J F Cubells; S Rayport; G Rajendran; D Sulzer
Journal:  J Neurosci       Date:  1994-04       Impact factor: 6.167

Review 9.  Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases.

Authors:  William J Burke; Shu Wen Li; Hyung D Chung; David A Ruggiero; Bruce S Kristal; Eugene M Johnson; Patricia Lampe; Vijaya B Kumar; Mark Franko; Evelyn A Williams; Daniel S Zahm
Journal:  Neurotoxicology       Date:  2004-01       Impact factor: 4.294

10.  Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity.

Authors:  W Michael Caudle; Jason R Richardson; Kristin C Delea; Thomas S Guillot; Minzheng Wang; Kurt D Pennell; Gary W Miller
Journal:  Toxicol Sci       Date:  2006-05-15       Impact factor: 4.849

View more
  32 in total

1.  Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.

Authors:  Shawn P Alter; Kristen A Stout; Kelly M Lohr; Tonya N Taylor; Kennie R Shepherd; Minzheng Wang; Thomas S Guillot; Gary W Miller
Journal:  Exp Neurol       Date:  2015-09-30       Impact factor: 5.330

2.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

3.  Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2015-02-25       Impact factor: 5.372

4.  The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein.

Authors:  Yunden Jinsmaa; Adele Cooney; Patricia Sullivan; Yehonatan Sharabi; David S Goldstein
Journal:  Neurosci Lett       Date:  2015-01-28       Impact factor: 3.046

5.  A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease.

Authors:  David S Goldstein; Patricia Sullivan; Courtney Holmes; Gary W Miller; Yehonatan Sharabi; Irwin J Kopin
Journal:  J Neurochem       Date:  2014-06-13       Impact factor: 5.372

6.  Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.

Authors:  Kelly M Lohr; Kristen A Stout; Amy R Dunn; Minzheng Wang; Ali Salahpour; Thomas S Guillot; Gary W Miller
Journal:  ACS Chem Neurosci       Date:  2015-03-09       Impact factor: 4.418

Review 7.  Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky.

Authors:  David S Goldstein; Irwin J Kopin
Journal:  Cell Mol Neurobiol       Date:  2017-05-09       Impact factor: 5.046

8.  Taurine protects noradrenergic locus coeruleus neurons in a mouse Parkinson's disease model by inhibiting microglial M1 polarization.

Authors:  Liyan Hou; Yuning Che; Fuqiang Sun; Qingshan Wang
Journal:  Amino Acids       Date:  2018-03-05       Impact factor: 3.520

Review 9.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Authors:  Kelly M Lohr; Shababa T Masoud; Ali Salahpour; Gary W Miller
Journal:  Eur J Neurosci       Date:  2016-09-02       Impact factor: 3.386

10.  Alpha-Synuclein Fibrils Interact with Dopamine Reducing its Cytotoxicity on PC12 Cells.

Authors:  Masoome Khalife; Dina Morshedi; Farhang Aliakbari; Amir Tayaranian Marvian; Hossein Mohammad Beigi; Sadegh Azimzadeh Jamalkandi; Francisco Pan-Montojo
Journal:  Protein J       Date:  2015-08       Impact factor: 2.371

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.